NCT04262661View on ClinicalTrials.gov

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions
Healthy VolunteersDiabetes Mellitus, Type 2
Interventions
DRUG

NNC0472-0147

Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.

DRUG

insulin glargine

Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.

DRUG

Placebo (NNC0472-0147)

Part 1: A single dose of placebo, dose increased in each cohort.

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT04262661 - A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes | Biotech Hunter | Biotech Hunter